• MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Dementia and Alzheimer Disease

The NeurologyLive dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.

Decompressive Craniectomy Shows Greater Improvements in Traumatic Intracranial Hypertension Than Standard Treatment

June 27, 2022

Article

Net improvement of 1 grade or more on Extended Glasgow Outcome Scale was observed in 30.4% of the surgical group compared with 14.5% of those on standard medical care.

This Week on NeurologyLive® — June 27, 2022

June 27, 2022

Article

Here's what is coming soon to NeurologyLive®.

NeurologyLive® Brain Games: June 26, 2022

June 26, 2022

Article

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

AbbVie Submits sNDA for Atogepant in Chronic Migraine, Semorinemab Fails in Phase 2 Prodromal Alzheimer Study, StrivePD Software Gets FDA Greenlight

June 25, 2022

Video

Neurology News Network for the week ending June 25, 2022. [WATCH TIME: 4 minutes]

NeurologyLive® Friday 5 — June 24, 2022

June 24, 2022

Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 24, 2022.

Fosgonimeton Fails to Reach End Points, but Shows Mechanistic Potential in Alzheimer Disease

June 23, 2022

Article

After 26 weeks of treatment, those on fosgonimeton alone without acetylcholinesterase inhibitors showed a potentially beneficial change in event-related potential P300 latency, an outcome of working memory processing speed.

Biogen Terminates Phase 4 ICARE-AD Trial of Aducanumab in Alzheimer Disease

June 23, 2022

Article

The trial was terminated because of the expectation of enrollment not being feasible, driven by the recent CMS national coverage determination. The phase 4 confirmatory ENVISION trial is still ongoing.

Semorinemab Demonstrates Safety, But No Slowing of Alzheimer Disease Progression

June 22, 2022

Article

Over an 18-month treatment period, patients with prodromal to mild Alzheimer disease demonstrated similar increases in Clinical Dementia Rating-Sum of Boxes scores regardless of treatment with placebo or semorinemab.

NeuroVoices: Ruth Benca, MD, PhD, on the Importance of Maintaining Quality Sleep and Lowering Alzheimer Disease Risk

June 22, 2022

Article

The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine discussed the major talking points regarding sleep quality, sleep disorders, and late-life neurocognitive issues.

Roche’s Crenezumab Fails to Meet End Points in Autosomal Dominant Alzheimer Disease

June 20, 2022

Article

In the first NIH-backed study to evaluate an experimental prevention therapy in cognitively unimpaired persons at risk for Alzheimer disease, crenezumab showed small numerical, but not statistically significant differences compared with placebo.